Stock Events

Relief Therapeutics SA 

$1.88
39
-$0.02-1.32% Wednesday 17:14

Statistics

Day High
1.93
Day Low
1.86
52W High
8.4
52W Low
0.01
Volume
1,855
Avg. Volume
3,615
Mkt Cap
143.53M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14AprExpected
Q2 2020
Q1 2021
Q2 2021
Q4 2021
Q2 2022
Q2 2023
Next
-0.01
-0.01
-0
0
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RLFTF. It's not an investment recommendation.

About

Health Technology
Biotechnology
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.
Show more...
CEO
Mr. Jack Weinstein
Employees
10
Country
CH
ISIN
CH0100191136

Listings